Combination therapy of GLP-1 analogues and insulin:do the benefits outweigh the costs?. Versmissen J. Netherlands Journal of Medicine . 2014Versmissen J... JVD Hilst,L Corluy,R Achten,... 被引量: 0发表: 2014年 A Critical Analysis of the Clinical Use of Incretin-Based Therapies In the...
Anti-diabetic therapy aims to lower blood glucose, wi... DL Connolly,SC Bain,E Collins,... - 《European Heart Journal》 被引量: 0发表: 2024年 Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured ...
The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. Curr Diab Rep 13: 307-318, 2013.Eckerle Mize DL, Salehi M. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 ...
point discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy....
图1 “一石二鸟”——Semaglutide可同时治疗肥胖和减轻骨关节炎疼痛,为其在六大方面的进一步研究和开发奠定基础。 《新英格兰医学杂志》最近发表了一项名为《每周一次Semaglutide治疗肥胖和膝关节骨关节炎患者》的临床研究,探索Semaglutide这一GLP-1 受体激动剂药物在减肥和缓解OA关节疼痛方面的功效。这项为期 68 周的...
AstraZeneca and Eccogene have entered into a license agreement for our internally-discovered, small molecule GLP-1r agonist, ECC5004. AstraZeneca is granted exclusive global rights for the development and commercialization of ECC5004 (also known as AZD5004) for any indication in all territories excep...
The US biotech’s Duchenne muscular dystrophy drug is “undoubtedly the most successful gene therapy launch in all of history,” according to CEO Doug Ingram. “We have barely scratched the surface of the opportunity in front of us.”
As cannabis becomes legal in more countries, further research is being conducted to determine the potential benefits and risks of cannabis-based products. It is expected that the trend toward cannabis-based nutraceuticals will continue to grow as more consumers become aware of their potential health ...
Direct costs of diverticulitis in a US managed care population. Am J Pharm Benefits. 2012;4(5):e118-e129.Google Scholar 5. Ambrosetti P. Value of CT for acute left-colonic diverticulitis: the surgeon’s view. Dig Dis. 2012;30(1):51-55.PubMedGoogle ScholarCrossref 6. Ambrosetti P,...
However, much of their initial improvement in cardiometabolic risk factors had been reversed. Further studies are needed to understand the potential long-term benefits and risks (ie, legacy effects) of such short-term therapy. The health benefits seen with continued treatment with the maximum ...